Early studies 1 ,2 showed that approximately 40% of patients with acquired immunodeficiency syndrome (AIDS) had neurological symptoms at some stage of their illness and that about 10% presented with neurological abnormalities-. However, neuropathological studies on postmortem material from AIDS patients have demonstrated abnormalities in a much higher proportiorr-". There is significant regional variation in the prevalence of certain neurological complications of HIV infection, eg cryptococcal meningitis being more common in New York than in the rest of the USA whereas the prevalence of progressive multifocalleucoencephalopathy appears to be uniforms, It is now apparent that any part of the neuro-axis may be affected following infection with HIV, albeit that the underlying pathological pathway in many conditions remains obscure, uncertainty also exists as to whether some neurological, neuropathological, or neuropsychiatric abnormalities can occur in HIV infectionwhich is otherwise asymptomatic or whether they are only related to advanced disease 7 -11 • The nervous system may be affected directly by HIV, opportunistic infection, neoplasia occurring secondary to immunodeficiency, by vascular events due to effects of HIV at sites remote to the nervous system, and as a complication of drug therapy. Multiple pathologies may occur within the nervous system, and while some syndromes are thought to be caused by a single infective agent, coinfection may be of importance in some individuals.
PRIMARY HIV SYNDROMES

AIDS dementia complex (ADC)
Early in the epidemic it was observed that some patients with AIDS had difficulty concentrating and become obtunded, these symptoms often being the harbinger of a progressive dementia. Thissyndrome was originally termed subacute encephalitis 2 ,11,12, Correspondence to: Dr 0 Rowen, Department of Genitourinary Medicine, Addenbrookes Hospital, Hills Road, Cambridge CB22QQ, UK however it has become apparent that motor deficit, ataxia and myoclonus are related features and this condition is therefore more commonly described as ,AIDS dementia complex'P.
Dementia is a common manifestation in HIVinfected people; in excess of 60% will show some degree of dementia during the course of their illness 7 ,14,15. It is important to differentiate dementia from the treatable 'pseudo-dementia' of depression. Impaired memory and diminished concentration span represent the commonest early manifestations of AIDS dementia complex's. As the disease progresses motor features such as weakness, ataxia, and myoclonus may be observed's. Late features, which sometimes develop rafidly, include mutism, paraparesis, incontinence! and, occasionally, fittingl,18. There is controversy surrounding the prevalence of neuropsychological deficit in HIV positive pe~le prior to the development of AIDS. Grant et al. reported the results of neuropsychological testing on 55 homosexual men whose HIV status ranged from being antibody negative to having AIDS. They reported that 86% of patients with AIDS had abnormalities demonstrable on psychometric testing. Also 54% of otherwise asymptomatic HIV antibody positive patients performed abnormally on psychometric tests compared to less than 10% of antibody negative controls. However, this study has been criticized on the grounds of small numbers of subjects and that the criteria used to define abnormality were unsound", Subsequent studies have failed to confirm the findings of Grant et aI. tO,11,19-22 Goethe et al.20 subjected 85 asymptomatic HIV antibody positive US airforce personnel to neutopsychological testing. Overall they found no significant differences between these, and mv seronegative control subjects. However, when those with known cerebrospinal fluid (CSF) abnormalities were tested they performed significantly less well on tasks of verbal memory. Broadly similar results were obtained by Janssen et al. 10 who concluded that there was no association between neuropsychological test results and absolute T-helper cell counts or estimated duration of HIV positivity. McArthur etal. ll found a low prevalence of neuropsychological abnormalities in otherwise healthy HIV antibody positive homosexual and bisexual men, CSF changes being noted in those performing normally and abnormally. In those asymptomatic subjects performing less well it was suggested that some abnormalities could be ascribed to other factors such as substance abuse.
The weight of evidence supports the view that asymptomatic HIV antibody positive individuals are not impaired neuropsychologicalll and furthermore a WHO consultation document/ stated that there was no justification in serological screening for HIV antibody in an attempt to detect functional impairment in asymptomatic persons.
The pathogenesis of AIDS dementia complex remains uncertain. One possibility is that HIV may disrupt neural function by direct infection of neurons and astrocytes either as a result of direct cytotoxicity, or indirectly by cytotoxic T-cells 24. However, HIV infection of neurons appears to be rare". In contrast cells of the macrophage/monocyte series in the brain are commonly infected 26, 27 , and neural cells may be damaged either via a bystander destructive effect or as a result of increased levels of monokines which are destructive to neural cells 28,29. Alternatively HIV infection of endothelial cells may result in disruption of the blood-brain barrier with deleterious consequences for the adjacent brain tissue 26. Finally, the envelope glycoprotein gp 120, may cause damage to the nervous system by competing with the neurotrophic property of vasoactive intestinal peptide (VIP) which despite its name is a neuropeptide", Another possibility is that AIDS Dementia Complex is caused, at least in part, by an agent other than HIV. Two viruses, cytomegalovirus (CMV) and
ICvirus have been suggested as cofactors 31,32. One or other of these viruses may act directly to disrupt neural function, or indirectly by causing an inflammatory response involving the accumulation of HIV-bearing macrophages.
Acute HIV meningo-encephalitis
This syndrome was first recognized prior to the discovery of HIV33 and initially described as atypical aseptic meningitis. Subsequently a rare condition with features of encephalitis was noted to occur at the time of seroconversione'. The clinical features include fever, headache, meningism, altered level of consciousness, and cranial nerve palsies, the fifth, seventh and eighth nerves being most commonly affected 1,2,34-36. Often this occurs at or about the time of sere-conversion as a part of a glandular fever like illness 34,35, although it may occur later in the illnessl-". This syndrome is markedly different to ADC in that it is self limiting34,35 whereas there is a relentless progression in ADC.
Vacuolar myelopathy
The pathological finding is often associated with ADC although not inevitably s038. The common presenting features are weakness in the lower limbs and incontinence-", the clinical findings are those of a spastic paraparesis and ataxia although signs may be confusing if there is an associated peripheral neuropathy (see below). Pathologically there is vacuolation in the dorsal columns, particularly in the thoracic region 39 ,40. Several theories as to the aetiology of this condition have been postulated including vitamin B12 deficiency due to nutritional factors-", drug inducedfl, viruses acting synergistically with HIV42 or HIV alone'", Many patients who have developed vacuolar myelopathy have subsequently been shown to have normal or near normal vitamin B12 levelsf', nor have they been exposed to drugs such as sulphonamides which had been incriminated, thereby excluding these factors as aetiological agents in the development of the myelopathy. Several groups have identified HIV in the spinal cords of these patients 41,42; however, others have failed to confirm this finding40. It is however, now regarded by most authorities as being due to the direct action of HIV. CMV has been reported to have been the causative agent in some cases of myelopathy, but in those, demyelination has been a prominent feature 43-45, thus distinguishing it pathologically from vacuolar myelopathy.
There is no successful treatment for this condition, although a therapeutic trial of antivirals such as ganciclovir may well be justified when faced with a paralysed, incontinent patient.
OPPORTUNISTIC VIRAL INFECTIONS JC virus
This papovavirus is the usual cause of the hitherto rare demyelinating disease proressive multifocal leucoencephalopathy (PML)46,4 which is usually associated with malignancies of the reticuloendothelial system such as Hodgkin's disease. PML is now recognized to occur in approximately 2% of AIDS patients coming to postmortem examinations".
The course of PML in AIDS patients is variable. Death usually occurs within one year of diagnosis; although long-term survival has been documentedw, it has never been reliably reported in AIDS patients and long-term survival in this group remains anecdotal. The condition presents with focal neurological symptoms and signs, mental deterioration, and cortical blindness is common'". Headache and fever are uncommon and this may help to differentiate it clinically from other opportunistic infections of the nervous system.
The condition may be reliably diagnosed on CT scanning of the brain. On CT scanning, nonenhancing hypodense lesions affecting the white matter are characteristic'".
There is no effective treatment for this condition; cytosine and infusion of HLA matched lymphocytes have been tried without significant success 1,53. Herpes simplex virus (HSV) encephalitis HSV encephalitis may take the acute haemorrhagic form as seen in immunocompetent subjects, or in marked contrast, a sub-acute form which may progress over several weeks 54 • Simultaneous infection with CMV appears common-v'". In addition to HSV I, the usual cause of herpes encephalitis in the immunocompetent, HSV II has been described as the causative agent in HIV positive patients'". Unlike HSV encephalitis in immunocompetent patients, in AIDS patients the process appears more widespread, and not confined to the temporal lobes. In the sub-acute presentation there is much less inflammatory response and haemorrhage. The presenting features of acute encephalitis include sudden onset of fitting, change in mentation and level of consciousness, headache and fever. In contrast the sub-acute form is characterized by weakness, lethargy and ataxia. Fitting, although known to occur, is not a dominant feature. A sub-clinical herpes encephalitis, diagnosed only at postmortem has also been described'", Herpes encephalitis can only be reliably diagnosed by brain biopsy. However, a high index of suspicion is required, and treatment with acyclovir initiated before awaiting results of a brain biopsy.
Cytomegalovirus (CMV)
CMV has been reported to cause a sub-acute encephalopathy in AIDS patients, and was thought by some authorities to be the aetiological agent of ADC (see above). CMV encephalitis is clinically indistinguishable from that caused by the direct action of HIV. CT scanning is generally unhelpful in distinguishing between CMV and HIV encephalitis, although biopsy proven multifocal CMV encephalitis has been demonstrated on magnetic resonance imaging (MRI).
Evidence is now emerging which would suggest, that in some cases polyradiculopathy associated with mv infection is due to CMV58,59. This radiculopathy tends to be progressive, leading to sacral sensory loss, urinary retention and flaccid paralysis over the course of a few weeks'". It would seem that such radiculopathies are a feature of end stage disease; all the patients reported by Miller etaI.59 had a previous AIDS encompassing diagnosis and had suffered substantial weight loss. Survival was of mean duration 5.8 weeks in the 5 patients who died. In those who survived the episode of radiculopathy, both were treated early in their illness with ganciclovir with a slow, but progressive improvement in neurological symptoms.
Inflammatory peripheral neuropathy has also been postulated to be caused by CMV in some HIV-infected patients 42 ,60,61, although others have implicated HIV as the primary causes' (see below),
Herpes zoster (HZ) encephalitis
Despite the association between HZ and defects of cell mediated immunity, and the relative frequency of cutaneous HZ in HIV antibody positive patients, there have been but few reports of HZ encephalitis in these patients. Evidence for HZ infection is often indirect 62 or speculative's. The encephalitis is clinically indistinguishable from that caused by other viruses, although the outcome is probably good unless there is disseminated infection. Treatment with high dose IV acyclovir may shorten the duration of the illness, but due to the small numbers of reported cases, no studies of long term efficacy of this drug in this condition have been reported.
NON-VIRAL OPPORTUNISTIC INFECTIONS
Cryptococcus neoformans
Cryptococcus neoformans is the commonest fungal pathogen to affect the CNS. It is often a late feature of HIV disease.
It may present acutelyM, in an indolent mannerM,65, or as an infection at another site 66 . Although cryptococcal meningitis is the commonest cryptococcal infection in HIV antibody positive patients the classical signs of meningism may be absents". Despite treatment of cryptococcal meningitis with amphotericin B it remains a disease with high mortality; immunodeficient patients, whatever the cause of their immunodeficiency experience much higher rates of treatment failure/", No regimen using amphotericin B in AIDS patients has been satisfactorily evaluated. Dosage, when used alone, is generally between 0.4 and 0.8 mg/k~day with a cumulative dose from 900 mg to 3 g64' . In AIDS patients with CNS disease, treated with amphotericin B, the survival is 70-80% at 6 weeks 67,68, The addition of flucytosine to the regimen has been shown to be more efficacious than am~hotericinB alone in immunocompetent patients 1, however this finding has not been confirmed in AIDS patients 65,67, although in both these studies numbers were small. Other drugs such as itraconazole, and fluconazole are currently being assessed as monotherapies 68 • 72,73. Whatever drug regimen is adopted, it does appear important to continue therapy until cultures of the CSF are repeatedly negative.
There are few consistent predictors of primary treatment failure. Relapse and CSF cryptococcal antigen titres in excess of 1 : 10,000 were associated with 100% mortalityM, whereas Chuck and Sande 67 found only positive cultures from extrameningeal sites and hyponatraemia were associated with an adverse outcome.
Relapse following apparently successful treatment of cryptococcal meningitis is common". However, the introduction of maintenance therapy has subsequently reduced the relapse rate 64, 67, 74 . As yet there is no consensus as to the dose, or frequency of administration of prophylactic amphotericin B. Dosage has ranged from 40 mg twice weekly to 100 mg weekly64. In a small series Sugar and Saunders" reported that fluconazole in doses of 50-200 mg/day may be a useful alternative to amphotericin B, especially as the drug is well tolerated, and may be taken orally. There is an obvious need for further studies, in order to assess the efficacy of fluconazole as an alternative prophylactic agent.
Toxoplasma gondii infection
Toxoplasma gondii is an obligate intracellular protozoal parasite whose definitive host is the cat. Transmission to man is by either the faecal-oral route, or by eating the undercooked meat of lamb, beef or pork (secondary hosts) which is infected with tissue cysts. The infective stage is the trophozoite (syn. tachyzoite) stage. Serological evidence suggests that infection occurs in 20-90% of the population of Europe and North America z,76. Most of these infections would have been sub-clinical, however in AIDS patients toxoplasmosis continues to be a significant cause of morbidity and mortality78-90.
Cerebral toxoplasmosis in HIV antibody positive patients presents in a sub-acute fashion 39.74. Prodromal non-specific symptoms such as fever, malaise, headache and confusion are common?". Focal deficits usually develop within a few weeks z.78 • Fitting occurs as an early manifestation in approximately 15%2. In contrast to ADC a change in conscious level occurs early in cerebral toxoplasmosis. Pathologically toxoplasma causes either a diffuse encephalitis or focal intracerebral lesions when it affects the nervous system. The pathological picture will determine which symptoms will predominate.
As there are no sensitive or specific non-invasive diagnostic tests a high index of suspicion is required, as early initiation of therapy is of the utmost importance if a successful outcome is to be achieved.
It is well documented that serum IgG antibodies to toxoplasma do not always increase significantly in patients with AIDS despite high parasite loads 3 ,79-82 . However local production of antibodies, giving rise to increased titres of CSF antibodies to toxoplasma may be of diagnostic value 82 ,83. CT or MRI scans may demonstrate single or multiple ringlike lesions which enhance on CT following injection of contrast5 2 • 84 • However the failure to demonstrate such lesions does not effectively exclude the diagnosis, as less specific abnormalities are sometimes found 85 -87, in addition neither forms of scanning are sufficiently specific to distinguish toxoplasmosis from cerebral lymphoma'Ss", although MRI scans are probably superior 74.84,87,88. The use of serial CT or MRI scans in assessing response to treatment is well established 52.88; both degree of enhancement and size of the lesion diminishing with successful treatment'".
The role of biopsy in the diagnosis of toxoplasmosis is contentious'". Moskowitz et «1. 89 advocated brain biopsy in AIDS patients with mass lesions demonstrable on scanning, because of the range of different pathology which could be the cause, requiring different treatment. This approach is, however, not widely accepted, many following a trial of therapy and reserving biopsy for those not making a satisfactory response to treatment 1,39.52,91,92. Furthermore, it should be noted that neither the sensitivity nor the specificity of biopsy reaches 100%as tissue cysts or tachyzoites are not always demonstrable on routine histological examination'S, and that the pleomorphic cellular response may appear ne0fslastic and could be confused with lymphoma'S 8. More sensitive and specific tests employing such techniques as the peroxidase-antiperoxidase rnethod'?, PAP methods? and immunohistochemical staining using antitoxoplasma sera 80 may increase the diagnostic yield.
Currently the most widely used treatment for toxoplasmosis is a combination of pyrimethamine, a dihydrofolate reductase inhibitor and sul~hadiazine, an inhibitor of dihydrofolatesynthetase 78 ••90. Folinic acid, a metabolite of folic acid is added, at a dosage of 15 mg daily to prevent folate deficiency. The optimum duration of therapy has yet to be clearly established; treatment being given for times ranging between 3 weeks to life-long or until side-effects necessitate cessation of therapy78,81,91.
A regimen of pyrimethamine 25-75 mg/day and sulfadiazine 75 mg/kg/day with or without loading doses is usually employed with satisfactory results during the acute phase of infection 74,90-94, with subsequent reduction in the sulfadiazine dose after 4-6 weeks'". Because of the high incidence of side effects of this regimen, usually attributable to the suphonamide, much effort has been directed towards finding alternative drugs. The clindamycin/ pyrimethamine combination has now become established as an alternative regimen 9S-97 with response rates broadly similar to that achieved with pyrimethamine/sulphadiazine 98.99 • However, the dosage of clindamycin in this combination has varied from 0.9 to 3.6 g/day. Clearly larger trials are necessary to define the most effective dose and duration of treatment with this drug combination. Other drugs such as trimetrexate'P' have been shown to inhibit toxoplasma in vitro; cotrimoxazole has recently been reported to be effective in the treatment of CNS toxoplasmosis'?'. These drugs warrant further investigation as to their efficacy in treating CNS toxoplasmosis.
One of the major therapeutic problems encountered in treating toxoplasmosis is that the drugs only affect the tachyzoite stage, thus any remaining tissue cysts have the potential to cause relapse, hence maintenance therapy must be instituted. Most authorities continue with the same drugs but at reduced dosage on a lifelong basis. Interesting data have emerged, albeit from a small trial, which suggests that a pyrimethamine/sulphadiazine combination, but not pyrimethamine/clindamycin may prove to be effective maintenance treatment when given on only 2 days per week 102 • As a high proportion of some populations show serological evidence of previous infection with toxoplasmosis (see above) it has been suggested that some HIV antibody positive patients may benefit from 'primary' prophllaxis against symptomatic toxoplasma infection'? . Ruf and Pohle 104 reported a small series in which toxoplasma prophylaxis (pyrimethamine/sulfadoxine) was given to patients known to have Pneumocystis carini pneumonia but not CNS toxoplasmosis; of 47 such patients only one developed CNS toxoplasmosis. However no time intervals are quoted. As yet it has not been possible to identify subgroups of toxoplasma antibody positive AIDS patients who would most benefit from 'primary prophylaxis'. Until this is established, the risk-benefit ratio cannot justify that all patients receive 'primary prophylaxis'
Mycobacterial infection
The incidence of mycobacterial infection of the CNS is markedly increased in AIDS patients, with Mycobacterium avium intracellulare (MAl) being much more commonly isolated than mycobacterium tuberculosts'P: although it has been postulated that MAl is not responsible for neurologic disability', others have attributed its presence in the CNS as the causative factor in production of symptoms". Mycobacterial infection, due to either mycobacteria tuberculosis or atypical mycobacteria, may present either sub-acutely with fever, headache, and changes in mentation; ie a meningitic picture or acutely with focal neurological features which are usually caused by a tuberculoma.
In AIDS patients with tuberculous meningitis (TBM) lumbar puncture reveals CSF with elevated protein, hypoglycorrhachia, and a predominantly lymphocytic pleocytosis. It is far from common to see or culture the organism'". These findings in the CSF may be seen with cryptococcosis (see above) but in the absence of cryptococcal antigen, it would be suggestive of mycobacterial infection. CT and MRI scanning are not specific enough to distinguish a tuberculoma from other mass lesions.
CNS tuberculosis appears to be more common in intravenous (iv) drug abusers than in other HIV antibod~positive patients 74 ,106 and in certain racial groups 1. MAl often occurs as disseminated disease and may be isolated from blood, urine and bone marrow 74 ; thus patients who are known iv drug abusers, come from countries in which tuberculosis is endemic, or have evidence of MAl at other sites and have neurological symptoms in the absence of any other diagnosable infection of the CNS should be started on antimycobacterial therapy. For treatment of mycobacterium tuberculosis (TBM) standard quadruple therapy of isoniazid, rifampicin, ethambutol and pyrazinamide is recommended. The role of steroids in treatment of TBM is controversiaf". Treatment of MAl is less satisfactoryl'". Currently regimens consisting of rifabutin, ethambutol, and clofazimine are recommendedl'". However, the efficacy of these regimens in treating CNS disease remains unproven. The quinolones, eg ciprofloxacin, ofloxacin, have aroused interest as bactericidal drugs against mycobacteria'w, their value in treating MAl infection of the CNS remains speculative.
OTHER INFECTIONS OF THE CNS
CNS infection with such agents as Candida albicans 1 , Aspergillus flavus and fumigatus 110 , mucormycales'P, and coccidioides'P have been reported albeit exceedingly rarely. The outcome of such infections is universally poor, most cases proving fatal.
TUMOURS OF THE CNS ASSOCIATED WITH HIV INFECTION
Primary cerebral lymphoma (PCL)
Primary cerebral lymphoma constitutes less than 2% of primary brain tumours-P. Their cause is unknown but many appear to be related to immunosuppression. It is however a relatively common tumour in patients infected with HIVI06, 114, 115. It has been estimated that it will be the most common brain tumour in the USA by the end of the century.
Presentation is non-specific: confusion, lethargy, and focal deficits being common-". Fitting has also been reported-F.
Histology is the only truly diagnostic test and as a result postmortem diagnosis is not unusual 117 ,118. Open brain or stereotactic biopsy of lesions noted on scanning and not responding to antitoxoplasma therapy, has confirmed the diagnosis in some patients-'". Scanning, although helpful in determining the site and size of lesions, is not diagnostic (see above). Lesions are most commonly supratentorial although multiple lesions frequently occur 113 ,120,121. Immunopathological studies have demonstrated that in immunocompromised Eatients PCL is derived from B cell lineage 117, 19 . There is no consistent histological appearance; immunoblastic, small non-cleaved lymphocytic and mixed tumours all being reported113,1~, 118. Response to treatment is disappointing. Median survival time without treatment is 1.8 months 113 • Even with the most aggressive treatment, 5-year survival is less than 5%113,120 in non-AIDS patients. Currently cranial irradiation therapy is the preferred mode of treatment in AIDS patients, total dosage ranging between 2200 and 6100cGy116,119,1~2. Although subjective improvement 1l6,119, tomographic improvement-" and increase in median survival to 10 months ll3 have been reported, there have not yet been any reports of long-term survival in AIDS patients. Drugs which are effective in controlling systemic non-Hodgkin lymphoma unfortunatel~show poor penetration of the bloodbrain barrier! ,113. This may therefore be a contributory factor for the poor response of PCL to agents such as vincristine, doxyrubicin and cyclophosphamide. There have not been any trials of chemotherapeutic agents against PCL in AIDS patients and reports are anecdotal. Combination chemotherapy of bleomycin, adriamycin, cyclophosphamide, vincristine, and dexamethasone (BACOD) as an adjuvant to cranial irradiation has been employed but without proven long-term efficacy119. Concern has been raised over the use of systemic chemotherapy in AIDS patients 122 on the grounds of its unproven effectiveness against PCL per se and also in producing more profound immunosuppression.
Cerebral astrocytoma
This tumour has been reI;rted to occur in HIV antibody positive patients . Presentation appears to be similar to that of any space occupying lesion. Diagnosis depends on histological examination of biopsy material. Prognosis is poor.
The paucity of literature concerning such tumours in HIV antibody positive patients suggests that the relationship is coincidental and not causal. However, it should be noted that multiple gliomata have been reported to occur in PML (see above), but in non-HIV antibody positive patients 124. Thus before any definitive statement can be made concerning these tumours, many more cases are required to be reported.
Metastatic tumours
Nodal non-Hodgkin's lymphoma is known to occur more frequently in HIV antibody positive patients than in the general population, furthermore metastatic spread to the CNS appears more common in AIDS patients 121. Presenting features depend on whether meningeal or dural disease predominates l 22 . Meningeal disease will lead to an encephalitic picture with cranial nerve palsies, whereas dural involvement leads to compressive symptoms; intracerebral masses are uncommon cf PCL.
Diagnosis of meningeal disease is dependent upon finding lymphoma cells in the CSF. If symptoms of compression of the brain or cord are present CT or MRI scanning will often determine the site and extent of disease.
Combination chemotherapy, including the use of intrathecal methotrexate and/or cytosine arabinoside is the mainstay of treatment for meningeal disease l 22 , whereas dural disease often responds well to radiotherapy and may be used as an emergency procedure in acute compressive myelopathy.
Kaposi's sarcoma rarely arises in (or metastasises to) the nervous system-, some series never finding this ghenomenon1,126. Of the 3 cases reported by Levy , 2 were postmortem diagnoses. Prognosis is therefore poor.
SYNDROMES OF UNCERTAIN AETIOLOGY
Peripheral neuropathy
At least 15% of AIDS patients have or have had abnormalities of the peripheral nervous system 1,2,60, although Jakobsen et al. 127 reported a much greater incidence of abnormality as assessed electrophysiologically, of the former groups approximately one-third have demonstrable infective causes 128 , the aetiology of the remainder is speculative.
Several distinct types of neuropathy are associated with HIV infection. These have been classified on the basis of the stage of the disease at which they occur 129 , on clinical and laboratory features l 30 , on histological features 131 and on the cell type predominantly effecteds", No classification is ideal and there is much overlap. Since the cell type affected will determine many of the clinical features of the neuropathy, for this discussion Dalakas's et al. 60 classification will be used.
Six sub-types are recognized: acute demyelinating inflammatory sensorimotor polyradiculopathy (ADISP), chronic inflammatory demyelinating polyneuropathy (CIDP), mononeuritis multiplex, distal symmetrical sensory painful polyneuropathy (distal axonopathy), sensory ataxic neuropathy (SAN) due to ganglioneuritis and a progressive inflammatory polyradiculopathy presenting as a cauda equina syndrome.
ADISP is indistinguishable from the Guillain-Barre syndrome 126 , which has been reported in association with seroconversion 132,133, ARC and AIDS129. The condition is of abrupt onset and leads to motor impairment usually affecting the lower limbs, although quadripleY1:a and cranial nerve palsies have been described 32. CSF protein is elevated 60, but unlike the Guillain-Barre syndrome there is a pleocytosis 129 ,134-136. Conduction studies usually confirm demyelination 129,136 as do histological studies-", Prognosis appears to be good, neurological function returning spontaneouslyv'-133, although it may be slow and incomplete'S.
CIDP differs from ADISP in that its mode of onset is progressive over 1-2 months. In common with ADISP a sensorimotor deficit occurs60,133, CSF proteins are elevated 13O,135 and a pleocytosis is found 60. Histologically, demyelination, which may be segmental, is observed 13O,138. This type of neuropathy is however generally associated with ARCljo,138 or asymptomatic disease 134,135 and does not seem to be associated with a seroconversion illnesss". Recovery of neurological function following plasmaphoresis has been reported 135,139, this however is far from being universall-".
Mononeuritis multiplex affects sensory, motor, or both fibres in multiple craniaI133, spinal'" and peripheral nerves 130. Presentation is an abrupt onset of a mononeuropathy followed bX further such episodes in other distributions-". Nerve conduction studies show this to be a patchy, multifocal process 60,13O. Histologically there is axonal degeneration and a necrotizing vasculitis l40,141. Patients with ARC or AIDS, but not asymptomatic HIV antibody positive, appear to be at risk from this particular form of neuropathy'?", Progression is variable. Some patients undergo spontaneous resolution whereas others progress to a sensorimotor neuropathy-". Immunosuppressive drugs do not appear to alter the outcomel'v.
Distal axonopathy is perhaps the most common of the neuropathiesw, and is usually associated with late stage disease 60,130,138. Sensory symptoms predominate 60,l42,l43, most patients complaining of painful paraesthesiae in the legs 1,2,60,142. Motor deficits are less pronounced'S'. Hyporeflexia is common, although often it is only the ankle jerks that are 10st 129,13O. Nerve conduction studies generally demonstrate mild slowing of conduction velocities 127,142 and absent sensory potentials'P. Patholo~ically there is evidence of axonal degeneration 60,18, predominantly affecting unmyelinated fibres'", Demyelination may also occur 138,142. Inflammatory changes are rare 60 and when present generally mild l38. This neuropathy does not usually remit and significant disability results'", Tricyclic antidepressants have been given to alleviate symptoms of paraesthesia, but with inconsistent degrees of benefit l42, 143.
SAN is perhaps the rarest of the neuropathies to be associated with HIV infection'v. The rarity of the association is such that it may well only be a chance finding. It appears to occur in early HIV infection, and is not steroid responsive. The association between HTLV-I and tropical ataxic neuropathy is establishedlf and with further investigation, SAN may be established as having a clear relationship to HIV.
Progressive inflammatory polyradiculo~athy may present as a cauda equina syndrome 60, 45, characterized by a flaccid paraparesis which may be asymmetrical, sphincter dysfunction, and sensory disturbance. This particular neuropathy, although having some clinicalfeatures that could be confused with CIDP, is pathologically quite distinct in that the lesions are confined to the dorsal roots 127. Electrophysiological studies show slowing of conduction velocities, prolonged latencies or loss of the F wave60,146. Myelography is essentially normal 60,147, but CSF protein is elevated and there is a pleocytosis60,l48. This neuropathy occurs late in the course of HIV infection 60,129,147 however in Przedborski's'w series, the clinical descriptions of which would fit this particular neuropathy, the patients spanned the spectrum of HIV disease. The clinical course is that of progressive impairments", althoulih in occasionalpatients the condition appears static! .
Autonomic neuropathy
Significant abnormalities of autonomic function have been described in several series148-150. Dysfunction may be asymptomatic and established only on clinical evaluations. Both parasympathetic abnormalities, as assessed by the Valsalva Manoeuvre and sympathetic abnormalities as determined by haemodynamic response to posture have been described 149,150. Autonomic dysfunction could not be established in asymptomatic HIV antibody positive patients (CDC group 11)149 but the degree of dysfunction did appear to correlate with the overall extent of HIV related nervous system diseasel'". Drugs such as vincristine's! and pentamidine-P may cause side effects leading to postural hypotension, and thus this finding alone, with a history of exposure to these drugs, would not conclusively support a diagnosis of autonomic neuropathy. If postural hypotension becomes problematical measures such as plasma volume expansion using o-fluorocortisone, or use of {3 blockers with intrinsic sympathomimetic activity eg oxprenolol, may be of value but there is no evidence of their efficacy in this scenario.
Cerebrovascular disease
Cerebrovascular disease may complicate HIV infection1,2. Clinically the incidence is between 1 and 7%3,4,153 whereas postmortem studies have demonstrated abnormalities in higher proportions 106,154. Thrombotic, embolic and haemorrhagic-154 events have been reported. Thrombosis often appears to be secondary to a vasculitis 154,155 which has also been demonstrated to cause amaurosis fugax 156. Other causes of thrombosis such as hyperviscosity syndrome-" and dehydration154 may be significant factors in some patients. Embolic stroke appears to be confined to patients with cardiac lesions or IV drug users l54,155. Haemorrhage may occur secondary to thrombocytopenial'f or rupture of a mycotic aneurysm, although the latter does not appear to be a particularly common occurrence-'". Engstrom et al. 158 have described transient neurological deficits in AIDS patients with and without infarction. Although often an infective cause was found, in many cases no such cause was determined. Interestingly they were unable to confirm the finding of fibroblast hyperplasia in the intima which has previouslr been reported to be found in patients with AIDS15. Symptoms and signs of cerebral infarction in AIDS patients are no different to those found in HIV antibody negative patients. Prognosis is related both to the size and site of the haemorrhage or infarction and to concomitant infections or neoplasia within the CNS.
CONCLUSIONS
Involvement of CNS in HIV infection is common and the cause of much morbidity and mortality. Prognosis, especially with infection, is dependent on prompt, effective treatment. For some conditions effective treatment is not available, but for other conditions treatment is effective if instituted early. A high index of suspicion is required if the correct diagnosis is to be made at an appropriately early stage of the illness. Ethical considerations need to be clarified with regard to treatment trials; although for some infections, eg cryptococcal meningitis, it would be clearly impossible to carry out certain double blind trials comparing maintenance therapy options, given the various routes of administration of the drugs, multicentre physician blinded trials could be carried out, and significant advances made.
Tumours, especially PCL carry a grave prognosis, and perhaps much earlier diagnosis of this condition and subsequent treatment by radiotherapy, may prove to be of greater benefit than treatment in the later stages of the illness. Again, controlled studies may demonstrate the relative efficacy of different treatment options, Since the recognition of AIDS much clinical information has been amassed, and treatment strategies proposed for treating CNS disease. If further progress is to be made it is essential that we now consolidate our knowledge, and address the issues with well designed, controlled trials, rather than to be left in a state of uncertainty as to the management of HIV antibody positive patients with nervous system disease.
